"Three years ago we acquired Metallicum Inc. another nano technology for advanced medicine, which propelled our company to a cash-flow-positive state. Together with our Fortune/1000 industrial partner (NYSE: CRS) we remain extremely optimistic about future prospects for our Metallicum unit. Now, with the acquisition of Senior Scientific, LLC, we anticipate repeating our history and expanding our overall business," Tsoupanarias said.

Marvin Maslow, Founder & Chairman Emeritus of Manhattan Scientifics, said, "The Senior Scientific technology is stunning and the enthusiastic acceptance of it for experimental clinical work by America's most important cancer hospitals and cancer research centers is equally stunning. Our team leaders, V. Gerald Grafe and Spencer Falk, in collaboration with Dr. Richard Larson of the University of New Mexico, have shown great determination to accelerate the commercialization process."

Edward R. Flynn, PhD, founder of Senior Scientific and Chief Scientist said, "I will continue to play a major role in developing this technology towards experimental and clinical applications. The past grants I received from the National Institutes of Health helped take the technology from concept to a working prototype. Now with the major commercializing role of Manhattan Scientifics, we can rapidly advance the technology from the laboratory to a clinical environment working cooperatively with the major cancer research centers in the U.S. This is truly an exciting time."

Source: Manhattan Scientifics